Skip to main content
. Author manuscript; available in PMC: 2021 Mar 28.
Published in final edited form as: Oncogene. 2020 Sep 28;39(45):6935–6949. doi: 10.1038/s41388-020-01479-6

Figure 1: Characterization of CWR22-RH.

Figure 1:

a) H & E histology (200x) of CWR22-RH xenografts. IHC staining (200x) for b) PTEN and c) AR. d) Western blot documenting AR expression in PC-82 relative to normal prostate, CWR22-RH, and LNCaP cells. e) m) Abi resistance of CWR22-RH xenografts in vivo (n = 3 each). f) Enzalutamide sensitivity of CWR22-RH xenografts in vivo (n = 5 each).